ArticleFrontiers in immunology2026

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells.

Susan Gellert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.